Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Net Cash Flow: 2021-2025

Historic Net Cash Flow for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$14.8 million.

  • ProQR Therapeutics N.V's Net Cash Flow fell 120.90% to -$14.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.9 million, marking a year-over-year increase of 134.66%. This contributed to the annual value of $29.0 million for FY2024, which is 13.81% up from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Net Cash Flow stood at -$14.8 million for Q3 2025, which was down 11.02% from -$13.4 million recorded in Q2 2025.
  • ProQR Therapeutics N.V's 5-year Net Cash Flow high stood at $88.3 million for Q2 2021, and its period low was -$59.9 million during Q3 2022.
  • For the 3-year period, ProQR Therapeutics N.V's Net Cash Flow averaged around $424,438, with its median value being -$7.3 million (2024).
  • Examining YoY changes over the last 5 years, ProQR Therapeutics N.V's Net Cash Flow showed a top increase of 4,272.45% in 2024 and a maximum decrease of 9,580.10% in 2024.
  • Over the past 5 years, ProQR Therapeutics N.V's Net Cash Flow (Quarterly) stood at $35.0 million in 2021, then slumped by 111.82% to -$4.1 million in 2022, then soared by 63.18% to -$1.5 million in 2023, then spiked by 4,272.45% to $63.5 million in 2024, then tumbled by 120.90% to -$14.8 million in 2025.
  • Its Net Cash Flow was -$14.8 million in Q3 2025, compared to -$13.4 million in Q2 2025 and -$17.4 million in Q1 2025.